

## **METHODOLOGICAL NOTE FOR TRANSFER OF VALUES MADE IN 2024**

### 1. Introduction

Ferring regularly works with HCP/HCOs. This Methodological note provides a summary of the methodologies used by Ferring Pharmaceuticals Limited in line with the ABPI Code of Practice 2024 to identify and report on Transfers of Value made directly or indirectly by Ferring, to or for the benefit of HCP/HCOs.

### 2. Definitions

**HCP:** An individual who is qualified to prescribe, administer, purchase, supply or recommend a Medicinal Product whose primary practice, principal professional address or place of incorporation is in UK

**HCO:** Any legal person (i) that is a healthcare, medical or scientific association or organization (irrespective of the legal or organizational form) such as a hospital, clinic, foundation, university or other teaching institution or learned society, whose business address, place of incorporation or primary place of operation is in UK or (ii) through which one or more HCPs provide services.

**ORDM:** Particularly includes someone with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who is not a health professional.

**TOV:** Transfer of Value - Direct and indirect TOV, whether in cash, in kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development and sale of prescription only medicine exclusively for human use. Direct TOVs are those made directly by Ferring for the benefit of a Recipient. Indirect TOVs are those made on behalf of Ferring for the benefit of a Recipient, or those made through a Third Party and where Ferring knows or can identify the Recipient that will benefit from the Transfer of Value. Aggregate ToVs are those which cannot be disclosed on an individual basis for legal reasons; the amounts attributable to such ToVs will be disclosed on an aggregate basis. The aggregate disclosure identifies (i) the number of Recipients covered by such disclosure, and (ii) the total amount attributable to ToV to such Recipients.

If a healthcare organisation consists of only one HCP or ORDM, then the TOV would be subject to the requirements in the Code regarding individual health professionals.

Where a TOV is made to an individual HCP or ORDA indirectly via a HCO, such a transfer will be disclosed once only, as being a transfer to the individual concerned.

Where TOV to HCPs or ORDMs is made by overseas affiliates or head offices of Ferring, and cannot be identified (where a lawful basis cannot be obtained), the amount attributable to such transfers will be disclosed on an aggregate basis; The number of recipients involved and the aggregate amount attributable to TOV to such recipients will be disclosed.

Donations, Grants,: Providing funds, benefits in-kind, or services freely given for the purpose of supporting healthcare, scientific research or education, with no consequent obligation on the recipient organisation, institution and the like to provide goods or services to Ferring to the benefit of Ferring in return. Donations and grants to HCPs are prohibited.

Sponsorship: a contribution, financial or otherwise, in whole or in part provided by or on behalf of Ferring, towards an activity (including an event/meeting or material) performed, organised, created by a healthcare organisation, patient organisation or other independent organisation.

Support: the provision of a financial contribution, in whole or in part, whether paid directly or indirectly to individual health professionals or other relevant decision makers to attend events/meetings, and includes payment for registration fees, travel and accommodation.

### 3. Completion of the ABPI Disclosure template

At the start of 2025, TOV disclosure data in respect of 2024 is inputted into the ABPI disclosure template from Financial Agreements (provision of support, sponsorship) and other payment agreements (research service agreements, IIS agreements, consultancy agreements, grants, donations, market research studies where identity of HCP/HCO is known to Ferring) made with the HCP/HCO/ORDM, and checked before uploading to the ABPI portal.

Contracted services such as chairing and speaking at meetings, assistance with training and participation in advisory boards, etc. are also disclosed as ToV. Such disclosure includes payments in relation to research and development work, including the conduct of clinical trials and real world evidence generation. Cross border transfer of values from Ferring affiliates towards UK HCPs and HCOs are also included in the submission. If one HCP/HCO has several countries of practices / registration, all the countries in which the HCP practices disclose the transfer of value / for an HCO the country where the assignment took place discloses the transfer of value.

Date of TOV is the date of the effective payment to the recipient.

In case of partial attendance or cancellation, or services not delivered, but value was transferred anyway e.g. according to contract clause, the transferred value is disclosed. If no value was transferred, the information on the TOV is not part of disclosure.

No collaborative working projects were conducted in 2024.

### 4. Transfer of Values made to Patient Organisations, Patients and Members of the UK Public

For transfers of value made to Patient Organisations and members of the UK public, including patients and journalists, disclosure information is published on the company's website

[Disclosures - Ferring UK](#).

## 5. How has consent been obtained

Consent to provide disclosure information of TOV is included as a part of the financial agreement/other payment agreement completed by the HCP/HCO with a clear Privacy disclaimer. Ferring relies on legitimate interests as its lawful basis for publicly disclosing ToVs to HCP/HCO/ORDM, unless an HCP/HCO/ORDM exercises their right to object to disclosure, and where such objection overrides Ferring's legitimate interests in disclosure.

## 6. Tax considerations

It is the responsibility of the HCP/HCO/ORDM to inform tax authorities of payments received as TOV from Ferring. Ferring is not responsible for providing information to tax authorities regarding payments made to HCP/HCO/ORDM.

## 7. VAT

VAT is not included in the payments.

## 8. Currency aspects

Conversion rates: All 2024 payments were made either in UK Pound Sterling, Kuwaiti Dollars, Swedish Kroner, Indian Rupees or Euro. Entries were converted to UK Pound Sterling using the following conversion rates:

EURO to UKP 1.67

SEK to UKP .077

KWD to UKP 2.5

INR to UKP 0.0090

## 9. Multi-year contracts

Only contracts with TOV where the payment was actually made in 2024 have been included in the 2024 disclosure. For contracts where the invoices are paid out in 2025, the disclosure will be made in 2026.

## 10. Over-the-counter transfers of value

According to 2024 Code of Practice, these are not required to be disclosed. Ferring didn't have any over-the-counter transfers of value for 2024.

## 11. Medical device transfers of value

No transfer of values were made for medical devices in 2024.